MiNK Therapeutics Secures $1.1M Non-Dilutive Funding in C-Further Pediatric Cancer Therapy Collaboration
INKT sits 60% above its 52-week low of $6.34.
Summary
MiNK Therapeutics announced a strategic collaboration with C-Further, an international pediatric oncology therapeutics consortium, to advance its PRAME-targeted iNKT cell therapy for pediatric cancers. The agreement includes approximately $1.1 million in non-dilutive funding to support IND-enabling development and a meaningful double-digit share of downstream commercial revenues. This collaboration provides crucial non-dilutive capital and external validation for a key pipeline asset, significantly enhancing the company's financial runway and de-risking the PRAME-TCR-iNKT program. Traders will watch for progress in preclinical studies and the nomination of a lead clinical candidate.
At the time of this announcement, INKT was trading at $10.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.1M. The 52-week trading range was $6.34 to $76.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.